A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

European Respiratory Journal

Volumn 19, Issue 2, 2002, Pages 217-224

  Casaburi, R ^a   Mahler, D A ^a   Jones, P W ^a   Wanner, A ^a   San Pedro, G ^a   ZuWallack, R L ^a   Menjoge, S S ^a   Serby, C W ^a   Witek, Jr ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic obstructive pulmonary disease; Dyspnoea; Exacerbations; Quality of life; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUCOCORTICOID; LACTOSE; OXYGEN; PLACEBO; PREDNISOLONE; PREDNISONE; SALBUTAMOL; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DRY POWDER; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPIROMETRY; XEROSTOMIA;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH STATUS; HUMANS; MALE; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SPIROMETRY;

EID: 0036181956     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00269802     Document Type: Article

References (32)

1. Management of chronic obstructive pulmonary disease
2. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
3. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease
4. Ipratropium bromide
5. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease
6. Tiotropium (Spiriva): Mechanistical considerations and clinical profile in obstructive lung disease
7. Tiotropium (Ba679). Pharmacology and early clinical observations
8. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD)
9. Effective use of Handihaler dry powder inhalation system over a range of COPD severity
10. Fifteen year interval spirometric evaluation of the Oregon predictive equations
11. Standardization of spirometry: 1994 update
12. The measurement of dyspnea: Contents, interobserver agreement and physiologic correlates of two new clinical indexes
13. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection
14. A self-complete measure for chronic airflow limitation - The St George's Respiratory Questionnaire
15. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD
16. Bronchodilator response in chronic obstructive pulmonary disease
17. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease
18. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways
19. Anticholinergics: Tiotropium
20. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD)
21. The timing of dose and pattern of bronchodilation of tiotropium (TIO) in stable COPD
22. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: A 13-week multicenter trial
23. The transition dyspnea index (TDI) in assessing improvements in breathlessness following tiotropium (TIO)
24. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease
25. The economic burden of COPD
26. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
27. Health status deterioration in patients with chronic obstructive pulmonary disease
28. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
29. Efficacy of salmeterol xinafoate in the treatment of COPD
30. Long term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium
31. Quality of life changes in COPD patients treated with salmeterol
32. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium